Clinical Trial Update: PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 % [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating pembrolizumab with or without chemotherapy in PD-L1–high non-small cell lung cancer, currently listed as active but not recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University Hospital, Brest | Conditions: Non-small-cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING